Citius Pharmaceuticals Inc CTXR
News
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
